Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hematological Disorders Clinical Trials

A listing of Hematological Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (26) clinical trials

Safety Study of SEA-CD40 in Cancer Patients

The study will be conducted in the following parts: Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological dose (OBD) regimens in patients with …

Phase

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PRIMARY OBJECTIVES: I. Determine safety and tolerability, and define the maximum tolerated dose of reolysin (wild-type reovirus), carfilzomib and dexamethasone in patients with relapsed multiple myeloma. II. Obtain evidence of reovirus entry into myeloma cells via localization of reoviral ribonucleic acid (RNA) in multiple myeloma (MM) cells (in situ hybridization …

Phase

The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

Chemotherapy induced anemia (CIA) is a common adverse event in cancer patients reported to occur in 20-60% whilst the resulting low hemoglobin level is associated with impaired quality of life. Lactoferrin (LF) is a non-haem iron-binding protein that is part of the transferrin protein family, along with serum transferrin, ovotransferrin, …

Phase

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

This is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of MGD013 administered by IV infusion every 2 weeks. The study consists of a Dose Escalation Phase to determine the MTD or maximum administered dose …

Phase

CAR-37 T Cells In Hematologic Malignancies

This is a two-part, non randomized, open label, single site Phase 1 study. Participants who fulfill eligibility criteria will be entered into the trial Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells). This study consists of 2 parts: Part A (Dose Escalation): The investigators are looking the highest dose …

Phase

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

PRIMARY OBJECTIVE: I. To determine the feasibility of implementing an individualized treatment strategy for advanced solid tumor and hematological malignancies based upon a comprehensive assessment of tumor and patient characteristics. SECONDARY OBJECTIVES: I. To describe the tolerability of implementing an individualized treatment strategy, particularly by measuring unanticipated toxicity associated with …

Phase

Dose Escalation Study of JNJ-64007957 a Humanized BCMA CD3 DuoBody Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The study will be conducted in 2 parts, separately for IV and SC administration: dose escalation (Part 1) and dose expansion (Part 2). It will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of JNJ-64007957 administered to adult participants with relapsed or refractory multiple myeloma. The overall safety of the …

Phase

A Study to Evaluate the Safety Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)

The drug being tested in this study is called TAK-981. TAK-981 is being tested to evaluate safety, tolerability, and PK in participants with advanced or metastatic solid tumors or relapsed/refractory hematologic malignancies and in a subset with COVID-19. The study will include a dose escalation phase and cancer treatment expansions …

Phase

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine in AML and high risk MDS patients, and to identify recommended doses for future studies.

Phase

A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors. TTI-621 (SIRPFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRP with the Fc domain of human immunoglobulin (IgG1). TTI-621 …

Phase